ABRIXONE ® is indicated for the treatment of Non-alcoholic fatty liver disease, is also indicated as an adjunct in the treatment of metabolic and structural alterations in the liver, consequent to acute and chronic alcohol intoxication, in particular by the fatty degeneration of the liver and alcoholic hepatitis. ABRIXONE ® is also indicated to complete the treatment regimen for initial and maintaining abstinence of alcoholics.
Contains: Metadoxine 500 mg
Route of Administration: Oral
Dosage Form: Tablets
Qty per package: 10 per Box
MFG or Dist.: EURODRUG LABORATORIES